NexImmune, Inc., a biopharmaceutical company, has announced the adjournment of its special meeting of stockholders originally convened on August 2, 2024. The meeting was scheduled to address the approval of the company's liquidation and dissolution, as well as the Plan of Liquidation and Dissolution. However, no business was conducted as the meeting was adjourned to allow the company more time to explore alternative strategies aimed at maximizing the value of its business and assets. The adjourned meeting is set to reconvene virtually on August 9, 2024, at 10:00 a.m. Eastern Time. The record date for determining stockholders entitled to vote remains June 11, 2024. Stockholders who have already voted do not need to take further action, and there have been no changes to the proposals...Show More

NexImmune, Inc., a biopharmaceutical company, has announced the adjournment of its special meeting of stockholders originally convened on August 2, 2024. The meeting was scheduled to address the approval of the company's liquidation and dissolution, as well as the Plan of Liquidation and Dissolution. However, no business was conducted as the meeting was adjourned to allow the company more time to explore alternative strategies aimed at maximizing the value of its business and assets. The adjourned meeting is set to reconvene virtually on August 9, 2024, at 10:00 a.m. Eastern Time. The record date for determining stockholders entitled to vote remains June 11, 2024. Stockholders who have already voted do not need to take further action, and there have been no changes to the proposals to be voted on. The company is actively soliciting additional votes from its stockholders during the adjournment period. As of the record date, NexImmune had 1,371,051 shares of common stock and one share of Series A Preferred Stock issued and outstanding. The company's filings with the SEC, including its latest annual report and the definitive proxy statement for the special meeting, contain important information for stockholders and are available on the SEC's website.